Table 1.

The IC₅₀s of BP in different tumors

Cell line	Tumor type	BP	Carmustine
Brain tumors
DBTRG-05MG	Human GBM cell	39.1 ± 1.7*	>100
GBM8401	Human GBM cell	21.1 ±1.5*	55.6 ± 9.6
GBM8901	Human GBM cell	28.9 ± 1.0*	56.5 ± 1.7
G5T/VGH	Human GBM cell	23.9 ± 0.9*	>100
RG2	Rat GBM cell	46.0 ± 2.7*	>100
SK-N-AS	Human neuroblastoma cell	67.4 ± 3.1*	>100
N18	Mouse neuroblastoma cell	15.5 ± 2.5*	>100
Other tumors
A549	Human lung cancer cell	32.1 ± 0.9*	>100
B16/F10	Mouse melanoma cell	24.3 ± 1.3*	69.9 ± 1.0
J5	Human hepatoma cell	19.5 ± 0.4*	49.2 ± 0.8
PA-1	Human teratoma cell	18.7 ±1.9*	54.7 ± 9.4
BCM-1	Human breast cancer cell	50.4 ± 0.7*	>100
HL-60	Human leukemia cell	26.6 ± 8.6*	40.2 ± 9.6
Normal cells
SVEC	Mouse vascular endothelia cell	25.0 ± 2.0†	34.5 ± 4.3
Balb/3T3	Mouse fibroblast cell	>100	>100

Note: Values are mean ± SD IC₅₀ (μg/mL) in day 2.

^*Significant difference from the BP versus Carmustine treatment in tumor cells (p < 0.001).

^†Significant difference from SVEC versus Balb/3T3 treatment with BP (p < 0.0001).